Medicure (TSXV:MPH) Tariff Resilience Score: 7/10 (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSXV:MPH Medicure Inc TSXV:MPH
57 GF Score
Price C$1.07
GF Value C$1.56
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Medicure Tariff Resilience Score?

Medicure TSXV:MPH +2.88% 57 Tariff Resilience Score is 7 as of Jul. 15, 2026. GuruFocus rates TSXV:MPH with a GF Score™ of 57/100 and a GF Value™ of C$1.56 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,029 Drug Manufacturers companies, Medicure ranks better than 97.08% on this metric.

Medicure has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Medicure has Medicure's operations are primarily in North America, with limited exposure to international tariffs. The pharmaceutical industry benefits from some tariff exemptions, and the company has strong pricing power. Historical tariff impacts have been minimal, and it has a robust domestic supply chain.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Medicure might have Highly Resilient.

Medicure  (TSXV:MPH) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Medicure Tariff Resilience Score Related Terms

TSXV:MPH vs ZTS, UTHR: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Medicure's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medicure Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medicure's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Medicure's Tariff Resilience Score falls into.


TSXV:MPH
57GF Score
Medicure Inc TSXV:MPH
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Medicure (TSXV:MPH) has a Tariff Resilience Score of 7 as of Jul. 15, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Medicure ranks #30 out of 1029 companies in the Drug Manufacturers industry, placing it in the top 2.9%.
Is Medicure's Tariff Resilience Score too high?
Medicure's current Tariff Resilience Score is 7. Based on the distribution chart, Medicure ranks #30 out of 1029 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Medicure has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Medicure's Tariff Resilience Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Medicure ranks #30 out of 1029 companies for Tariff Resilience Score. This places Medicure in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Medicure's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicure stock overvalued right now?
Based on GuruFocus' analysis, Medicure (TSXV:MPH) is currently considered Possible Value Trap. The stock's GF Value™ is C$1.56, compared to a current price of C$1.07 — trading 31.4% below its estimated fair value. The current Tariff Resilience Score is 7. Medicure's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Medicure (TSXV:MPH), the current Tariff Resilience Score is 7 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medicure (TSXV:MPH) Overvalued in 2026?

Based on GuruFocus' analysis, Medicure stock appears to be undervalued. The current stock price of C$1.07 is trading 31.4% below its estimated GF Value™ of C$1.56. GuruFocus considers Medicure to be Possible Value Trap.

Key valuation signals for TSXV:MPH:

  • Tariff Resilience Score: 7
  • GF Value™: C$1.56 vs. price of C$1.07 (31.4% below fair value)
  • GF Score™: 57/100 with 4 warning signs

No single metric tells the full story. See the TSXV:MPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medicure Business Description

Other Exchanges MCUJF:USA
Address 1250 Waverley Street, No. 2, Winnipeg, MB, CAN, R3T 6C6
Medicure Inc is focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market and sales to the Retail Public of pharmaceutical products. The Company's present focus is the sale and marketing of its cardiovascular products, AGGRASTAT, ZYPITAMAG, and increasing its e-commerce and mail order pharmaceutical business. The Company operates under two segments: the marketing and distribution of commercial products and the operation of a retail and mail order pharmacy. It generates the majority of its revenue from the Retail and Mail Order Pharmacy segment.
57GF Score

Get the complete analysis for TSXV:MPH

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$1.07
Price
C$1.56
GF Value